Article Text
Statistics from Altmetric.com
Cardenas-de la Garza et al 1 ask a reasonable question that nowadays likely resonates in many rheumatological practices: “Should we screen our patients who start biologics for SARS-CoV-2?” As so often in medicine, the question is easily asked but is more difficult to answer.
First of all, screening implies the availability of a diagnostic test to be applied in a patient that does not have symptoms (yet). For SARS-CoV-2, we have two types of tests available: the PCR test, known as the ‘swab-test’, which proves the presence of the virus, and the antibody test, which proves the presence …
Footnotes
Handling editor Josef S Smolen
Contributors Both authors contributed to the preparation of this response.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Commissioned; internally peer reviewed.